BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer 2019;7:183. [PMID: 31307554 DOI: 10.1186/s40425-019-0647-4] [Cited by in Crossref: 148] [Cited by in F6Publishing: 160] [Article Influence: 37.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Xu J, Cui Z, Wu S, Xie T, Zhang X. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1071675] [Reference Citation Analysis]
2 Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, de Castro G Jr, Turna HZ, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, Herbst RS. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. Ann Oncol 2023:S0923-7534(23)00049-2. [PMID: 36709038 DOI: 10.1016/j.annonc.2023.01.011] [Reference Citation Analysis]
3 Moon S, Kim HJ, Lee Y, Lee YJ, Jung S, Lee JS, Hahn SH, Kim K, Roh JY, Nam S. Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma. Comput Biol Med 2023;154:106602. [PMID: 36716688 DOI: 10.1016/j.compbiomed.2023.106602] [Reference Citation Analysis]
4 Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36670267 DOI: 10.1038/s41575-022-00736-1] [Reference Citation Analysis]
5 Wang M, Yang X, Meng Y, Jin Z, Cao J, Xiong L, Xiong Z. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma. Int Immunopharmacol 2023;115:109660. [PMID: 36623412 DOI: 10.1016/j.intimp.2022.109660] [Reference Citation Analysis]
6 Park YS, Kook M, Kim B, Lee HS, Kang D, Gu M, Shin OR, Choi Y, Lee W, Kim H, Song IH, Kim K, Kim HS, Kang G, Park DY, Jin S, Kim JM, Choi YJ, Chang HK, Ahn S, Chang MS, Han S, Kwak Y, Seo AN, Lee SH, Cho M, The Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. A Standardized Pathology Report for Gastric Cancer: 2nd Edition. J Gastric Cancer 2023;23. [DOI: 10.5230/jgc.2023.23.e7] [Reference Citation Analysis]
7 Park YS, Kook MC, Kim BH, Lee HS, Kang DW, Gu MJ, Shin OR, Choi Y, Lee W, Kim H, Song IH, Kim KM, Kim HS, Kang G, Park DY, Jin SY, Kim JM, Choi YJ, Chang HK, Ahn S, Chang MS, Han SH, Kwak Y, Seo AN, Cho MY. A standardized pathology report for gastric cancer: 2nd edition. J Pathol Transl Med 2023;57:1-27. [PMID: 36647283 DOI: 10.4132/jptm.2022.12.23] [Reference Citation Analysis]
8 Safa H, Abu Rous F, Belani N, Borghaei H, Gadgeel S, Halmos B. Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. Target Oncol 2022. [PMID: 36577876 DOI: 10.1007/s11523-022-00937-3] [Reference Citation Analysis]
9 Markham JF, Fellowes AP, Green T, Leal JL, Legaie R, Cullerne D, Morris T, John T, Solomon B, Fox SB. Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02105-w] [Reference Citation Analysis]
10 Provencio M, Ortega AL, Coves-sarto J, Calvo V, Marsé-fabregat R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León-mateos L, Sánchez-torres JM, Sullivan IG, Cobo M, Sánchez-hernández A, Massuti B, Sierra-rodero B, Mártinez-toledo C, Serna-blasco R, Romero A, Cruz-bermúdez A. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden. JAMA Oncol 2022. [DOI: 10.1001/jamaoncol.2022.5959] [Reference Citation Analysis]
11 Gao L, Wang X, Wang X, Wang F, Tang J, Ji J. A prognostic model and immune regulation analysis of uterine corpus endometrial carcinoma based on cellular senescence. Front Oncol 2022;12:1054564. [PMID: 36568182 DOI: 10.3389/fonc.2022.1054564] [Reference Citation Analysis]
12 Nie L, Zhang Y, You Y, Lin C, Li Q, Deng W, Ma J, Luo W, He H. The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients. Hematology 2022;27:840-8. [PMID: 35924822 DOI: 10.1080/16078454.2022.2107970] [Reference Citation Analysis]
13 Cai X, Liang X, Wang K, Liu Y, Hao M, Li H, Dai X, Ding L. Pyroptosis-related lncRNAs: A novel prognosis signature of colorectal cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.983895] [Reference Citation Analysis]
14 Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol 2022;13:1032314. [PMID: 36483562 DOI: 10.3389/fimmu.2022.1032314] [Reference Citation Analysis]
15 Ghazi B, El Ghanmi A, Kandoussi S, Ghouzlani A, Badou A. CAR T-cells for colorectal cancer immunotherapy: Ready to go? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.978195] [Reference Citation Analysis]
16 Fang H, Bertl J, Zhu X, Lam TC, Wu S, Shih DJ, Wong JW. Tumour mutational burden is overestimated by target cancer gene panels. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.10.004] [Reference Citation Analysis]
17 Imyanitov E, Sokolenko A. Integrative Genomic Tests in Clinical Oncology. IJMS 2022;23:13129. [DOI: 10.3390/ijms232113129] [Reference Citation Analysis]
18 Nishi T, Togashi Y. Translational Research in Cancer Immunotherapies. JJLC 2022;62:363-370. [DOI: 10.2482/haigan.62.363] [Reference Citation Analysis]
19 Boudin L, Morvan JB, Thariat J, Métivier D, Marcy PY, Delarbre D. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. Curr Oncol 2022;29:7718-31. [PMID: 36290887 DOI: 10.3390/curroncol29100610] [Reference Citation Analysis]
20 Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, Xu W, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, Choueiri TK, Schrag D, Carrot-Zhang J, Gusev A. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell 2022;40:1161-1172.e5. [PMID: 36179682 DOI: 10.1016/j.ccell.2022.08.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
21 Sartore-Bianchi A, Agostara AG, Patelli G, Mauri G, Pizzutilo EG, Siena S. Application of histology-agnostic treatments in metastatic colorectal cancer. Dig Liver Dis 2022;54:1291-303. [PMID: 35701319 DOI: 10.1016/j.dld.2022.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Jia Z, Long D, Yu Y. Dynamic Expression of Palmitoylation Regulators across Human Organ Development and Cancers Based on Bioinformatics. CIMB 2022;44:4472-4489. [DOI: 10.3390/cimb44100306] [Reference Citation Analysis]
23 Cui G, Liu J, Wang C, Gu R, Wang M, Sun Z, Wei F. Comprehensive analysis of the prognostic signature and tumor microenvironment infiltration characteristics of cuproptosis-related lncRNAs for patients with colon adenocarcinoma. Front Oncol 2022;12:1007918. [DOI: 10.3389/fonc.2022.1007918] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Provinciali N, Paleari L, Briata IM, Piccardo A, Bacigalupo L, Rutigliani M, Decensi A. Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report. Current Problems in Cancer: Case Reports 2022;7:100172. [DOI: 10.1016/j.cpccr.2022.100172] [Reference Citation Analysis]
25 Jin C, Zhao JS, Huang XQ, Yang XZ, Niu FY, Lin JR, Ma L, Shi YX, Li XS, Jiang P, Gao S, Li F, Song Y. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35947245 DOI: 10.1007/s12072-022-10375-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Makrooni MA, O'Sullivan B, Seoighe C. Bias and inconsistency in the estimation of tumour mutation burden. BMC Cancer 2022;22:840. [PMID: 35918650 DOI: 10.1186/s12885-022-09897-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Park S, An J, Ha SY, Nam S, Kim JH. Immune signature as a potential marker for predicting response to immunotherapy in obesity-associated colorectal cancer. J Gastroenterol Hepatol 2022;37:1579-87. [PMID: 35680621 DOI: 10.1111/jgh.15909] [Reference Citation Analysis]
28 Iannantuono GM, Torino F, Rosenfeld R, Guerriero S, Carlucci M, Sganga S, Capotondi B, Riondino S, Roselli M. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. IJMS 2022;23:8535. [DOI: 10.3390/ijms23158535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Damato A, Rotolo M, Caputo F, Borghi E, Iachetta F, Pinto C. New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. Life (Basel) 2022;12:1137. [PMID: 36013315 DOI: 10.3390/life12081137] [Reference Citation Analysis]
30 Pesta M, Shetti D, Kulda V, Knizkova T, Houfkova K, Sharif Bagheri M, Svaton M, Polivka J. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics 2022;12:1799. [DOI: 10.3390/diagnostics12081799] [Reference Citation Analysis]
31 Chen Z, Feng R, Kahlert UD, Chen Z, Torres-Dela Roche LA, Soliman A, Miao C, De Wilde RL, Shi W. Construction of ceRNA Networks Associated With CD8 T Cells in Breast Cancer. Front Oncol 2022;12:883197. [PMID: 35756601 DOI: 10.3389/fonc.2022.883197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Gupta P, Jindal A, Ahuja G, Jayadeva, Sengupta D. A new deep learning technique reveals the exclusive functional contributions of individual cancer mutations. J Biol Chem 2022;:102177. [PMID: 35753349 DOI: 10.1016/j.jbc.2022.102177] [Reference Citation Analysis]
33 Lau TTY, Sefid Dashti ZJ, Titmuss E, Pender A, Topham JT, Bridgers J, Loree JM, Feng X, Pleasance ED, Renouf DJ, Schrader KA, Sun S, Ho C, Marra MA, Laskin J, Karsan A. The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. J Mol Diagn 2022;24:609-18. [PMID: 35367630 DOI: 10.1016/j.jmoldx.2022.02.004] [Reference Citation Analysis]
34 Gan M, Zhang C, Qiu L, Wang Y, Bao H, Yu R, Liu R, Wu X, Shao Y, Hou P, Fei Z. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients. Cancer Med 2022. [PMID: 35586877 DOI: 10.1002/cam4.4725] [Reference Citation Analysis]
35 Shaikhha A, Huot M, Smith J, Olteanu D. Functional collection programming with semi-ring dictionaries. Proc ACM Program Lang 2022;6:1-33. [DOI: 10.1145/3527333] [Reference Citation Analysis]
36 González-Barrios R, Alcaraz N, Montalvo-Casimiro M, Cervera A, Arriaga-Canon C, Munguia-Garza P, Hinojosa-Ugarte D, Sobrevilla-Moreno N, Torres-Arciga K, Mendoza-Perez J, Diaz-Chavez J, Cortes-González CC, Castro-Hernández C, Martínez-Cedillo J, Scavuzzo A, Pérez-Montiel D, Jiménez-Ríos MA, Herrera LA. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy. Cancers (Basel) 2022;14:2065. [PMID: 35565196 DOI: 10.3390/cancers14092065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol 2022. [PMID: 35378995 DOI: 10.2217/fon-2021-1647] [Reference Citation Analysis]
38 Ning B, Liu Y, Wang M, Li Y, Xu T, Wei Y. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;13:748674. [PMID: 35355708 DOI: 10.3389/fphar.2022.748674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Geidel G, Heidrich I, Kött J, Schneider SW, Pantel K, Gebhardt C. Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. NPJ Precis Oncol 2022;6:17. [PMID: 35322182 DOI: 10.1038/s41698-022-00261-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Zhao C, Xiong K, Ji Z, Liu F, Li X, Poggi A. The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis. Oxidative Medicine and Cellular Longevity 2022;2022:1-28. [DOI: 10.1155/2022/8297011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Fancello L, Guida A, Frige G, Ceol AGM, Babini G, Scaglione GL, Zanfardino M, Mazza T, Ferrando L, Pelicci PG, Mazzarella L. TMBleR: a bioinformatic tool to optimize TMB estimation and predictive power. Bioinformatics 2022;38:1724-6. [PMID: 34927668 DOI: 10.1093/bioinformatics/btab836] [Reference Citation Analysis]
42 Bradley JR, Cannings TI. Data-driven design of targeted gene panels for estimating immunotherapy biomarkers. Commun Biol 2022;5:156. [PMID: 35197525 DOI: 10.1038/s42003-022-03098-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Liu Y, Gusev A, Heng YJ, Alexandrov LB, Kraft P. Somatic mutational profiles and germline polygenic risk scores in human cancer. Genome Med 2022;14:14. [PMID: 35144655 DOI: 10.1186/s13073-022-01016-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Khwaja RM, Chu QS. Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. Current Oncology 2022;29:479-89. [DOI: 10.3390/curroncol29020043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer 2022;10:e003231. [PMID: 35022192 DOI: 10.1136/jitc-2021-003231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
46 Iftikhar M, Younis A, Lee YS, Shehzad A. Introduction to Cancer Biomarkers. Cancer Biomarkers in Diagnosis and Therapeutics 2022. [DOI: 10.1007/978-981-16-5759-7_1] [Reference Citation Analysis]
47 Pereira MA, de Oliveira Marinho FL, Leite LR, Alvim LB, Malta FSV, Marques FK, de Lima AB. Breast Cancer and Next-Generation Sequencing: Towards Clinical Relevance and Future. Breast Cancer: From Bench to Personalized Medicine 2022. [DOI: 10.1007/978-981-19-0197-3_20] [Reference Citation Analysis]
48 Solis Soto LM, Wang H. Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_115-1] [Reference Citation Analysis]
49 Luo Y, Chen Q, Lin J. . MBE 2022;19:7055-75. [DOI: 10.3934/mbe.2022333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Geanta M, Boata A, Brand A, Cucos B, Lehrach H. Precision Medicine in Oncology and Cancer Therapeutics. Precision Medicine in Clinical Practice 2022. [DOI: 10.1007/978-981-19-5082-7_3] [Reference Citation Analysis]
51 Kim M, Seo AN. Molecular Pathology of Gastric Cancer. J Gastric Cancer 2022;22:264. [DOI: 10.5230/jgc.2022.22.e35] [Reference Citation Analysis]
52 Aiyer KTS, Doeleman T, Ryan NA, Nielsen M, Crosbie EJ, Smit VTHBM, Morreau H, Goeman JJ, Bosse T. Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis. Mod Pathol 2022;35:1775-83. [PMID: 36104536 DOI: 10.1038/s41379-022-01149-w] [Reference Citation Analysis]
53 Liu J, Chen T, Yang M, Zhong Z, Ni S, Yang S, Shao F, Cai L, Bai J, Yu H. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma. Front Cell Dev Biol 2021;9:753004. [PMID: 34901000 DOI: 10.3389/fcell.2021.753004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Conroy JM, Pabla S, Glenn ST, Seager RJ, Van Roey E, Gao S, Burgher B, Andreas J, Giamo V, Mallon M, Lee YH, DePietro P, Nesline M, Wang Y, Lenzo FL, Klein R, Zhang S. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One 2021;16:e0260089. [PMID: 34855780 DOI: 10.1371/journal.pone.0260089] [Reference Citation Analysis]
55 Ota N, Yoshimoto Y, Darwis NDM, Sato H, Ando K, Oike T, Ohno T. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol 2021. [PMID: 34860358 DOI: 10.1007/s11604-021-01230-5] [Reference Citation Analysis]
56 Zhao J, Dong Y, Bai H, Duan J, Wang G, Xu J, Wang J, Wang Z. Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. Journal of the National Cancer Center 2021. [DOI: 10.1016/j.jncc.2021.11.006] [Reference Citation Analysis]
57 Mancini M, Righetto M, Noessner E. Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. Cancers (Basel) 2021;13:6016. [PMID: 34885126 DOI: 10.3390/cancers13236016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
58 Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 2021;:1-7. [PMID: 34793275 DOI: 10.1080/13543784.2022.2008354] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
59 Li L, Bai Y, Gao Y, Li D, Chen L, Zhou C, Feng M, Chen X, Jin W, Cao Y. Systematic Analysis Uncovers Associations of PGK1 with Prognosis and Immunological Characteristics in Breast Cancer. Dis Markers 2021;2021:7711151. [PMID: 34790279 DOI: 10.1155/2021/7711151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Ba H, Liu L, Peng Q, Chen J, Zhu YD. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 2021;21:1220. [PMID: 34774004 DOI: 10.1186/s12885-021-08924-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Li L, Bai L, Lin H, Dong L, Zhang R, Cheng X, Liu Z, Ouyang Y, Ding K. Multiomics analysis of tumor mutational burden across cancer types. Comput Struct Biotechnol J 2021;19:5637-46. [PMID: 34745455 DOI: 10.1016/j.csbj.2021.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
62 Zhao C, Liu Y, Ju S, Wang X. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker. Int J Gen Med 2021;14:7411-22. [PMID: 34744452 DOI: 10.2147/IJGM.S331752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Zhang S, Gong C, Ruiz-Martinez A, Wang H, Davis-Marcisak E, Deshpande A, Popel AS, Fertig EJ. Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response. Immunoinformatics (Amst) 2021;1-2:100002. [PMID: 34708216 DOI: 10.1016/j.immuno.2021.100002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
64 Li Y, Luo Y. Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. Sci Rep 2021;11:21072. [PMID: 34702927 DOI: 10.1038/s41598-021-00626-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 2021;17:3837-49. [PMID: 34671202 DOI: 10.7150/ijbs.64077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
66 Sorokin M, Gorelyshev A, Efimov V, Zotova E, Zolotovskaia M, Rabushko E, Kuzmin D, Seryakov A, Kamashev D, Li X, Poddubskaya E, Suntsova M, Buzdin A. RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples. Front Oncol 2021;11:732644. [PMID: 34650919 DOI: 10.3389/fonc.2021.732644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Pham TV, Goodman AM, Sivakumar S, Frampton G, Kurzrock R. Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. Genome Med 2021;13:159. [PMID: 34641956 DOI: 10.1186/s13073-021-00979-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Huang T, Yan T, Chen G, Zhang C. Development and Validation of a Gene Mutation-Associated Nomogram for Hepatocellular Carcinoma Patients From Four Countries. Front Genet 2021;12:714639. [PMID: 34621291 DOI: 10.3389/fgene.2021.714639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, Chen SJ, Baden J, Carl Barrett J, Beer P, Butler M, Cheng JH, Conroy J, Cyanam D, Eyring K, Garcia E, Green G, Gregersen VR, Hellmann MD, Keefer LA, Lasiter L, Lazar AJ, Li MC, MacConaill LE, Meier K, Mellert H, Pabla S, Pallavajjalla A, Pestano G, Salgado R, Samara R, Sokol ES, Stafford P, Budczies J, Stenzinger A, Tom W, Valkenburg KC, Wang XZ, Weigman V, Xie M, Xie Q, Zehir A, Zhao C, Zhao Y, Stewart MD, Allen J; TMB Consortium. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol 2021;32:1626-36. [PMID: 34606929 DOI: 10.1016/j.annonc.2021.09.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
70 Tang B, Zhu J, Zhao Z, Lu C, Liu S, Fang S, Zheng L, Zhang N, Chen M, Xu M, Yu R, Ji J. Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden. J Adv Res 2021;33:153-65. [PMID: 34603786 DOI: 10.1016/j.jare.2021.01.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
71 Chen Z, Wang M, De Wilde RL, Feng R, Su M, Torres-de la Roche LA, Shi W. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype. Front Immunol 2021;12:749459. [PMID: 34603338 DOI: 10.3389/fimmu.2021.749459] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
72 Cao R, Ma B, Wang G, Xiong Y, Tian Y, Yuan L. Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer. Mol Ther Oncolytics 2021;22:277-93. [PMID: 34553019 DOI: 10.1016/j.omto.2021.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
73 Weber LM, Hippen AA, Hickey PF, Berrett KC, Gertz J, Doherty JA, Greene CS, Hicks SC. Genetic demultiplexing of pooled single-cell RNA-sequencing samples in cancer facilitates effective experimental design. Gigascience 2021;10:giab062. [PMID: 34553212 DOI: 10.1093/gigascience/giab062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Cho YA, Lee H, Kim DG, Kim H, Ha SY, Choi YL, Jang KT, Kim KM. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cancers (Basel) 2021;13:4659. [PMID: 34572886 DOI: 10.3390/cancers13184659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Smith J, Shi Y, Benedikt M, Nikolic M. Scalable analysis of multi-modal biomedical data. Gigascience 2021;10:giab058. [PMID: 34508579 DOI: 10.1093/gigascience/giab058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C. Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors. Immunotherapy 2021;13:1205-13. [PMID: 34494466 DOI: 10.2217/imt-2021-0024] [Reference Citation Analysis]
77 Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? J Immunother Cancer 2020;8:e000475. [PMID: 32238471 DOI: 10.1136/jitc-2019-000475] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
78 Cho J, Yoon SE, Kim SJ, Ko YH, Kim WS. Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. BMC Cancer 2021;21:972. [PMID: 34461835 DOI: 10.1186/s12885-021-08695-7] [Reference Citation Analysis]
79 Vyse S, Thway K, Huang PH, Jones RL. Next-generation sequencing for the management of sarcomas with no known driver mutations. Curr Opin Oncol 2021;33:315-22. [PMID: 33927108 DOI: 10.1097/CCO.0000000000000741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
80 Lin PC, Yeh YM, Hsu HP, Chan RH, Lin BW, Chen PC, Pan CC, Hsu KF, Hsiao JR, Shan YS, Shen MR. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers. Cancers (Basel) 2021;13:4317. [PMID: 34503126 DOI: 10.3390/cancers13174317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Wojas-Krawczyk K, Paśnik I, Kucharczyk T, Wieleba I, Krzyżanowska N, Gil M, Krawczyk P, Milanowski J. Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. Int J Mol Sci 2021;22:9133. [PMID: 34502043 DOI: 10.3390/ijms22179133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Boesch M, Baty F, Rothschild SI, Tamm M, Joerger M, Früh M, Brutsche MH. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021;125:313-23. [PMID: 33824481 DOI: 10.1038/s41416-021-01365-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
83 Park S, Lee C, Ku BM, Kim M, Park W, Kim NKD, Ahn M. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. BMB Rep 2021;54:386-91. [DOI: 10.5483/bmbrep.2021.54.7.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Huo C, Zhang MY, Li R, Liu TT, Li JP, Qu YQ. Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures. Front Cell Dev Biol 2021;9:645482. [PMID: 34368114 DOI: 10.3389/fcell.2021.645482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 You H, Xu-Monette ZY, Wei L, Nunns H, Nagy ML, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Van Krieken JH, Piris MA, Winter JN, Li Y, Au Q, Xu B, Albitar M, Young KH. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology 2021;10:1928365. [PMID: 34350060 DOI: 10.1080/2162402X.2021.1928365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 Liu H, Gao L, Xie T, Li J, Zhai TS, Xu Y. Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes. Front Oncol 2021;11:623313. [PMID: 34336641 DOI: 10.3389/fonc.2021.623313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
87 Zhao H, Danli S, Qian Z, Ye S, Chen J, Tang Z. Identifying GNG4 might play an important role in colorectal cancer TMB. Cancer Biomark 2021. [PMID: 34275892 DOI: 10.3233/CBM-203009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon EB, Zhou XJ. Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nat Commun 2021;12:4172. [PMID: 34234141 DOI: 10.1038/s41467-021-24457-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
89 Meng Q, Li CX, Long D. CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity. Int J Gen Med 2021;14:3197-211. [PMID: 34262333 DOI: 10.2147/IJGM.S318278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211024460. [PMID: 34262612 DOI: 10.1177/17562848211024460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Eltahir M, Isaksson J, Mattsson JSM, Kärre K, Botling J, Lord M, Mangsbo SM, Micke P. Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. Cancers (Basel) 2021;13:3116. [PMID: 34206510 DOI: 10.3390/cancers13133116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, Tian J, Gillies RJ, Schabath MB. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer 2021;9:e002118. [PMID: 34135101 DOI: 10.1136/jitc-2020-002118] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
93 Addeo A, Friedlaender A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol 2021;163:103374. [PMID: 34087341 DOI: 10.1016/j.critrevonc.2021.103374] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 19.0] [Reference Citation Analysis]
94 Dumoulin DW, Dingemans AC, Aerts JGJV, Remon J, De Ruysscher DKM, Hendriks LEL. Immunotherapy in small cell lung cancer: one step at a time: a narrative review. Transl Lung Cancer Res 2021;10:2970-87. [PMID: 34295691 DOI: 10.21037/tlcr-20-630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Gautam S, Kachroo S, DeClue RW, Fisher MD, Basu A. Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population. J Comp Eff Res 2021;10:857-68. [PMID: 34047199 DOI: 10.2217/cer-2020-0288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Caruntu A, Moraru L, Lupu M, Ciubotaru DA, Dumitrescu M, Eftimie L, Hertzog R, Zurac S, Caruntu C, Voinea OC. Assessment of Histological Features in Squamous Cell Carcinoma Involving Head and Neck Skin and Mucosa. J Clin Med 2021;10:2343. [PMID: 34071843 DOI: 10.3390/jcm10112343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
97 Park S, Lee JC, Choi CM. Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice. J Clin Med 2021;10:2236. [PMID: 34064038 DOI: 10.3390/jcm10112236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 He Y, Chen L, Zhao L, Dang S, Liu G, Sasada S, Ma PC, van Zandwijk N, Rosell R, Popper HH, Wang H, Jiang M, Guo H, Liu X, Chen S, Zhang X, Xu M, Zhu B, Liu M, Zhou C. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. Theranostics 2021;11:7092-109. [PMID: 34093873 DOI: 10.7150/thno.58039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
99 Caruntu A, Moraru L, Lupu M, Vasilescu F, Dumitrescu M, Cioplea M, Popp C, Dragusin A, Caruntu C, Zurac S. Prognostic Potential of Tumor-Infiltrating Immune Cells in Resectable Oral Squamous Cell Carcinoma. Cancers (Basel) 2021;13:2268. [PMID: 34066837 DOI: 10.3390/cancers13092268] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
100 Zhang W, Wang R, Fang H, Ma X, Li D, Liu T, Chen Z, Wang K, Hao S, Yu Z, Chang Z, Na C, Wang Y, Bai J, Zhang Y, Chen F, Li M, Chen C, Wei L, Li J, Chang X, Qu S, Yang L, Huang J. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing. Clin Transl Med 2021;11:e415. [PMID: 34047470 DOI: 10.1002/ctm2.415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
101 Fenizia F, Alborelli I, Costa JL, Vollbrecht C, Bellosillo B, Dinjens W, Endris V, Heydt C, Leonards K, Merkelback-Bruse S, Pfarr N, van Marion R, Allen C, Chaudhary R, Gottimukkala R, Hyland F, Wong-Ho E, Jermann P, Machado JC, Hummel M, Stenzinger A, Normanno N. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. J Mol Diagn 2021;23:882-93. [PMID: 33964449 DOI: 10.1016/j.jmoldx.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Martínez-Pérez E, Molina-Vila MA, Marino-Buslje C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. NPJ Precis Oncol 2021;5:31. [PMID: 33850256 DOI: 10.1038/s41698-021-00169-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Xiang S, Li J, Shen J, Zhao Y, Wu X, Li M, Yang X, Kaboli PJ, Du F, Zheng Y, Wen Q, Cho CH, Yi T, Xiao Z. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:653836. [PMID: 33897701 DOI: 10.3389/fimmu.2021.653836] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
104 Shum B, Larkin J, Turajlic S. Predictive biomarkers for response to immune checkpoint inhibition. Semin Cancer Biol 2021:S1044-579X(21)00097-3. [PMID: 33819567 DOI: 10.1016/j.semcancer.2021.03.036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
105 Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, Jordaens S, Baggerman G, Sorber L, Roeyen G, Peeters M, Pauwels P. Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle. Cancers (Basel) 2021;13:1675. [PMID: 33918147 DOI: 10.3390/cancers13071675] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
106 Jean-Baptiste SR, Feigenberg SJ, Dorsey JF, Kao GD. Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer. Semin Radiat Oncol 2021;31:149-54. [PMID: 33610272 DOI: 10.1016/j.semradonc.2020.11.002] [Reference Citation Analysis]
107 Indini A, Nigro O, Lengyel CG, Ghidini M, Petrillo A, Lopez S, Raspagliesi F, Trapani D, Khakoo S, Bogani G. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. Cancers (Basel) 2021;13:1663. [PMID: 33916221 DOI: 10.3390/cancers13071663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
108 Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol 2021;11:617335. [PMID: 33777757 DOI: 10.3389/fonc.2021.617335] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
109 Lumish MA, Cercek A. Immunotherapy for the treatment of colorectal cancer. J Surg Oncol 2021;123:760-74. [PMID: 33595891 DOI: 10.1002/jso.26357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
110 Inoue H, Tomida S, Horiguchi S, Kato H, Matsuoka H, Sanehira E, Matsuoka M, Yanai H, Hirasawa A, Toyooka S. Best practices for the extraction of genomic DNA from formalin-fixed paraffin-embedded tumor tissue for cancer genomic profiling tests. Pathol Int 2021;71:360-4. [PMID: 33657250 DOI: 10.1111/pin.13086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Caruntu A, Scheau C, Tampa M, Georgescu SR, Caruntu C, Tanase C. Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. Adv Exp Med Biol 2021. [PMID: 33650087 DOI: 10.1007/5584_2021_626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
112 O'Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget 2021;12:394-400. [PMID: 33747355 DOI: 10.18632/oncotarget.27877] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
113 Jonna S, Vanderwalde A, Nieva J, Poorman KA, Saul M, von Buttlar X, Hu JY, Liu SV. Effect of prior therapy on tumor mutational burden in NSCLC. Transl Lung Cancer Res 2021;10:1231-8. [PMID: 33889505 DOI: 10.21037/tlcr-20-1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Inoue K, Kai K, Sato S, Nishida H, Hirakawa K, Nasu K, Narahara H. Mixed large and small cell neuroendocrine carcinoma and endometrioid carcinoma of the endometrium with high microsatellite instability: A case report and literature review. SAGE Open Med Case Rep 2021;9:2050313X21999200. [PMID: 33738100 DOI: 10.1177/2050313X21999200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, Blank CU. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 2021;27:256-63. [PMID: 33558721 DOI: 10.1038/s41591-020-01211-7] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 51.5] [Reference Citation Analysis]
116 Liu Y, Gusev A, Heng YJ, Alexandrov LB, Kraft P. Somatic mutational profiles and germline polygenic risk scores in human cancer.. [DOI: 10.1101/2021.01.28.428663] [Reference Citation Analysis]
117 Giunta EF, Pappalardo A, Trapani D, Petrillo A. An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. Ovarian Cancer Biomarkers 2021. [DOI: 10.1007/978-981-16-1873-4_2] [Reference Citation Analysis]
118 Vogel A, Bathon M, Saborowski A. Immunotherapies in clinical development for biliary tract cancer. Expert Opin Investig Drugs 2021;30:351-63. [PMID: 33382361 DOI: 10.1080/13543784.2021.1868437] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
119 Smith J, Shi Y, Benedikt M, Nikolic M. Scalable Analysis of Multi-Modal Biomedical Data.. [DOI: 10.1101/2020.12.14.422781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Cesano A, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karanikas V, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Thorsson V, Tschernia N, Wang E, Wells DK, Wyant TL, Rutella S. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges. J Immunother Cancer 2020;8:e001472. [PMID: 33323463 DOI: 10.1136/jitc-2020-001472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
121 Del Re M, Cucchiara F, Rofi E, Fontanelli L, Petrini I, Gri N, Pasquini G, Rizzo M, Gabelloni M, Belluomini L, Crucitta S, Ciampi R, Frassoldati A, Neri E, Porta C, Danesi R. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunol Immunother 2021;70:1667-78. [PMID: 33315149 DOI: 10.1007/s00262-020-02810-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
122 Thakral D, Gupta R, Sahoo RK, Verma P, Kumar I, Vashishtha S. Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA. Front Cell Dev Biol 2020;8:604391. [PMID: 33363162 DOI: 10.3389/fcell.2020.604391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
123 Lee YG, Chang H, Keam B, Chun SH, Park J, Park KU, Shin SH, An HJ, Lee KE, Lee KW, Kim HR, Kim SB, Ahn MJ, Hwang IG. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. Cancer Res Treat 2021;53:671-7. [PMID: 33285051 DOI: 10.4143/crt.2020.824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
124 Sajjadi E, Venetis K, Scatena C, Fusco N. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? Ecancermedicalscience 2020;14:1150. [PMID: 33574895 DOI: 10.3332/ecancer.2020.1150] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
125 Wojas-Krawczyk K, Kubiatowski T. Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research. Front Oncol 2020;10:568174. [PMID: 33330041 DOI: 10.3389/fonc.2020.568174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
126 Shemesh CS, Chan P, Legrand FA, Shames DS, Das Thakur M, Shi J, Bailey L, Vadhavkar S, He X, Zhang W, Bruno R. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacol Res Perspect 2020;8:e00685. [PMID: 33241650 DOI: 10.1002/prp2.685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
127 Sutherland KD, Vissers JHA. Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment. J Thorac Oncol 2020;15:1106-9. [PMID: 32593443 DOI: 10.1016/j.jtho.2020.03.012] [Reference Citation Analysis]
128 Weber LM, Hippen AA, Hickey PF, Berrett KC, Gertz J, Doherty JA, Greene CS, Hicks SC. Genetic demultiplexing of pooled single-cell RNA-sequencing samples in cancer facilitates effective experimental design.. [DOI: 10.1101/2020.11.06.371963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Hu H, Cai W, Wu D, Hu W, Dong Wang L, Mao J, Zheng S, Ge W. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. Cancer Med 2021;10:135-42. [PMID: 33125191 DOI: 10.1002/cam4.3579] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
130 Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 2021;39:154-73. [PMID: 33125859 DOI: 10.1016/j.ccell.2020.10.001] [Cited by in Crossref: 141] [Cited by in F6Publishing: 174] [Article Influence: 47.0] [Reference Citation Analysis]
131 Krebs FS, Gérard C, Wicky A, Aedo-Lopez V, Missiaglia E, Bisig B, Trimech M, Michielin O, Homicsko K, Zoete V. Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology. Int J Mol Sci 2020;21:E8021. [PMID: 33126538 DOI: 10.3390/ijms21218021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Bracci L, Fragale A, Gabriele L, Moschella F. Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. Front Immunol 2020;11:582744. [PMID: 33193392 DOI: 10.3389/fimmu.2020.582744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
133 Inaba-Higashiyama R, Yoshida T, Jo H, Shirasawa M, Motoi N, Ohe Y. Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series. Thorac Cancer 2020;11:3618-21. [PMID: 33085191 DOI: 10.1111/1759-7714.13713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
134 Gjoerup O, Brown CA, Ross JS, Huang RSP, Schrock A, Creeden J, Fabrizio D, Tolba K. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS J 2020;22:132. [PMID: 33057937 DOI: 10.1208/s12248-020-00514-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
135 Imamura Y, Toihata T, Haraguchi I, Ogata Y, Takamatsu M, Kuchiba A, Tanaka N, Gotoh O, Mori S, Nakashima Y, Oki E, Mori M, Oda Y, Taguchi K, Yamamoto M, Morita M, Yoshida N, Baba H, Mine S, Nunobe S, Sano T, Noda T, Watanabe M. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. Int J Cancer 2021;148:1260-75. [PMID: 32997798 DOI: 10.1002/ijc.33322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Kim S, Lee JW, Park YS. The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers. Life (Basel) 2020;10:E228. [PMID: 33023080 DOI: 10.3390/life10100228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
137 Jiang J, Ding Y, Wu M, Chen Y, Lyu X, Lu J, Wang H, Teng L. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. Cancer Med 2020;9:8498-518. [PMID: 32969604 DOI: 10.1002/cam4.3481] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
138 Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020;21:1353-1365. [PMID: 32919526 DOI: 10.1016/S1470-2045(20)30445-9] [Cited by in Crossref: 672] [Cited by in F6Publishing: 526] [Article Influence: 224.0] [Reference Citation Analysis]
139 Gao L, Meng J, Zhang Y, Gu J, Han Z, Wang X, Gao S. Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer. Genomics 2020;112:4980-92. [PMID: 32882325 DOI: 10.1016/j.ygeno.2020.08.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
140 Li R, Han D, Shi J, Han Y, Tan P, Zhang R, Li J. Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. Biochim Biophys Acta Rev Cancer 2020;1874:188420. [PMID: 32828886 DOI: 10.1016/j.bbcan.2020.188420] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
141 Donoghue MTA, Schram AM, Hyman DM, Taylor BS. Discovery through clinical sequencing in oncology. Nat Cancer 2020;1:774-83. [DOI: 10.1038/s43018-020-0100-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
142 Hirsch D, Gaiser T, Merx K, Weingaertner S, Forster M, Hendricks A, Woenckhaus M, Schubert T, Hofheinz RD, Gencer D. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. J Cancer Res Clin Oncol 2021;147:263-73. [PMID: 32776177 DOI: 10.1007/s00432-020-03335-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Wang Y, Chen L, Ju L, Xiao Y, Wang X. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. Int Immunopharmacol 2020;87:106818. [PMID: 32738594 DOI: 10.1016/j.intimp.2020.106818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
144 Kim SY, Halmos B. Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Manag 2020;9:LMT36. [PMID: 32774467 DOI: 10.2217/lmt-2020-0003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
145 Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. Biomolecules 2020;10:E1061. [PMID: 32708698 DOI: 10.3390/biom10071061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
146 Bonanno L, Pavan A, Ferro A, Calvetti L, Frega S, Pasello G, Aprile G, Guarneri V, Conte P; Rete Oncologica Veneta (ROV). Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. Oncologist 2020;25:e1996-2005. [PMID: 32557976 DOI: 10.1634/theoncologist.2020-0148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
147 Cao R, Yuan L, Ma B, Wang G, Tian Y. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother 2021;70:1-18. [DOI: 10.1007/s00262-020-02649-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
148 Kujala J, Hartikainen JM, Tengström M, Sironen R, Kosma VM, Mannermaa A. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival. Cancer Med 2020;9:5922-31. [PMID: 32602248 DOI: 10.1002/cam4.3258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
149 Gao L, Meng J, Zhang Y, Gu J, Han Z, Gao S, Wang X. Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer.. [DOI: 10.1101/2020.06.28.175984] [Reference Citation Analysis]
150 Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology 2020;9:1781997. [PMID: 32923144 DOI: 10.1080/2162402X.2020.1781997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Lin YC, Chen YC, Chen RY, Huang YX, Tu SJ, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, Chang YY, Chen SW, Chang JG. Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy. Int J Mol Sci 2020;21:E4117. [PMID: 32527042 DOI: 10.3390/ijms21114117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Caracciolo D, Riillo C, Arbitrio M, Di Martino MT, Tagliaferri P, Tassone P. Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. Int J Cancer 2020;147:2658-68. [PMID: 32383203 DOI: 10.1002/ijc.33038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
153 Heeke S, Benzaquen J, Hofman V, Long-Mira E, Lespinet V, Bordone O, Marquette CH, Delingette H, Ilié M, Hofman P. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability. J Thorac Oncol 2020;15:1535-40. [PMID: 32450274 DOI: 10.1016/j.jtho.2020.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
154 Sundar R, Smyth EC, Peng S, Yeong JPS, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Front Oncol 2020;10:763. [PMID: 32500029 DOI: 10.3389/fonc.2020.00763] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
155 Teixido C, Reguart N. Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective). Future Oncol 2020;16:1677-81. [PMID: 32407147 DOI: 10.2217/fon-2020-0171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
156 Annaratone L, Cascardi E, Vissio E, Sarotto I, Chmielik E, Sapino A, Berrino E, Marchiò C. The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. Pathobiology 2020;87:125-42. [PMID: 32325459 DOI: 10.1159/000507055] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
157 Heeke S, Benzaquen J, Hofman V, Long-mira E, Lespinet V, Bordone O, Marquette C, Delingette H, Ilié M, Hofman P. Brief Report: Correlation cannot be used to compare sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer.. [DOI: 10.1101/2020.03.28.20046102] [Reference Citation Analysis]
158 Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers (Basel) 2020;12:E473. [PMID: 32085544 DOI: 10.3390/cancers12020473] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
159 Cai H, Zhang Y, Zhang H, Cui C, Li C, Lu S. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J Surg Oncol 2020;121:1007-14. [PMID: 31995247 DOI: 10.1002/jso.25859] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
160 Li S, Noor Z, Zeng W, Ni X, Yuan Z, Alber F, Li W, Garon EB, Zhou XJ. Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis.. [DOI: 10.1101/2019.12.31.19016253] [Reference Citation Analysis]
161 Zhao J, Dong Y, Ba H, Duan J, Wang G, Xu J, Wang Z, Wang J. The Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-Analysis. SSRN Journal. [DOI: 10.2139/ssrn.3738656] [Reference Citation Analysis]
162 Tomasini P, Greillier L. Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer? Transl Lung Cancer Res 2019;8:S323-6. [PMID: 32038906 DOI: 10.21037/tlcr.2019.09.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
163 Wu Y, Xu J, Du C, Wu Y, Xia D, Lv W, Hu J. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2019;9:1161. [PMID: 31750249 DOI: 10.3389/fonc.2019.01161] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
164 Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Adv Ther 2019;36:2638-78. [PMID: 31410780 DOI: 10.1007/s12325-019-01051-z] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 25.3] [Reference Citation Analysis]